Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
about
Calcitonin and calcitonin receptors: bone and beyondG protein-coupled receptors: what a difference a 'partner' makesThe role of SERMs in the management of postmenopausal osteoporosis.Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture.Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsComparative safety of bone remodeling agents with a focus on osteoporosis therapies.Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Treatment of osteopenia.Comparing therapies for postmenopausal osteoporosis prevention and treatment.Medical treatment of vertebral osteoporosisGuidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of GastroenterologyManagement of established osteoporosisOsteoporosis: the increasing role of the orthopaedist.Use of osteoporosis medications in older nursing facility residents.Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.Managing elderly people's osteoporosis. Why? Who? How?A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women - study protocol.Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents.Osteoporosis update: effective prevention and treatment.New developments in the treatment of osteoporosis.Salmon calcitonin use and associated cancer risk.When the government actively faces the burden of osteoporosis: the Italian experience.Prevention of fractures in the elderly. A review.Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?The future of ipriflavone in the management of osteoporotic syndromes.Development of clinical practice guidelines for prevention and treatment of osteoporosis.Osteoporosis. Current pharmacologic options for prevention and treatment.Prevention of osteoporotic fractures--should orthopedic surgeons care?The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review.Management of patients with vertebral compression fractures.Symposium overview: estrogens and antiestrogens in managing the patient with breast cancer.The impact of kyphosis on daily functioning.A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.How well are community-living women treated for osteoporosis after hip fracture?
P2860
Q24643368-F829732A-F8BB-42DC-A1AA-60DADABCBEE3Q27023482-1D2C36BF-65A4-46B0-A3B0-96A22DF369CBQ33757760-222A7C64-97B7-4BE6-ACD1-757FC140142DQ34044762-27F04781-E7F2-46DB-ABAD-8AA960FBD912Q34118797-720BF602-D3CA-4BD0-A7F4-9FE6C808C200Q34195727-41E1C794-D46A-4CE0-BD42-A1C1A0F763C0Q34273006-799F0547-8FD6-44A1-BBB3-A2D116DC368AQ34300668-F79423E4-B3D8-451F-AE54-C9ED8A29D19BQ34630644-0B20B851-26F2-49F6-BE83-50B06BBB6948Q35112397-D52236F2-6B0A-4796-B030-C1D1E756CBCEQ35299212-7EE1C629-01DB-47F6-926B-45139574D15FQ35579293-2EE67728-A524-47C7-BBB7-E1E668F11406Q35802137-6AB7F441-8560-42A3-8FAB-6B1AB2A6B38EQ35836987-23F7840D-9CC2-407A-98FE-AFE2BCA4DD6DQ36147387-477E2D57-7B8C-4507-A284-46BA2E9C6157Q36577487-486E0ED3-478D-42DC-869A-DB980B88A7B5Q36577705-779E018F-E025-474F-9A6E-04FDAF80BA62Q36638556-94E3F474-7FF9-4684-ABC9-6787A535B4C7Q37436438-08A71699-26E5-47F8-A8D9-5D487A3E529FQ37763162-337FF6EC-E2DF-41CE-93E2-B8B35F18B230Q38014515-F0B98D05-6AF5-4785-9432-25C297B207B5Q38164665-CE644D7A-D7D5-4BDE-8AA3-969879B206BBQ39506166-7ABDFE05-6AEE-44EF-A561-D367C7C3ACD3Q40597874-A8BAB596-B637-4DAA-902C-42C2B121D4F3Q40867107-F2C82F54-CC04-4F63-9D43-401EBC5E682BQ40911840-FCC7880D-A8BE-4714-A0BB-1E0BD5CB40E6Q40955435-5B49128C-5679-428F-8D76-F1ABBA397E81Q41329621-3EEC18AC-18F2-414A-9162-9963E1D264B4Q43749300-5BE7348C-D893-4297-A8BB-8A72D0590A76Q48014983-2400C777-2231-4FB7-AFBD-BCB1D75B4B9BQ50637578-9308657C-5098-4464-A2D7-EA1145BEAFFFQ50665292-0F60F187-1E0A-4E4B-A84A-4483FE173CEBQ50918827-C2E29874-FE56-431D-B0BF-AECD35607614Q51580931-8D6799E8-CD24-4AE6-96D6-94780C8B4F6AQ51963621-81C02589-6A89-41ED-8DB8-4AEBB8733F6A
P2860
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Effect of salcatonin given int ...... orosis: a dose-response study.
@ast
Effect of salcatonin given int ...... orosis: a dose-response study.
@en
type
label
Effect of salcatonin given int ...... orosis: a dose-response study.
@ast
Effect of salcatonin given int ...... orosis: a dose-response study.
@en
prefLabel
Effect of salcatonin given int ...... orosis: a dose-response study.
@ast
Effect of salcatonin given int ...... orosis: a dose-response study.
@en
P2093
P2860
P356
P1433
P1476
Effect of salcatonin given int ...... orosis: a dose-response study.
@en
P2093
C Christiansen
K Overgaard
M A Hansen
S B Jensen
P2860
P304
P356
10.1136/BMJ.305.6853.556
P407
P577
1992-09-01T00:00:00Z